Current opinion in obstetrics & gynecology
-
Curr. Opin. Obstet. Gynecol. · Feb 2010
ReviewDuration of adjuvant endocrine therapy of breast cancer: how much is enough?
To describe the current status regarding the duration of adjuvant tamoxifen and/or aromatase inhibitors in women with early-stage hormone receptor positive breast cancer. ⋯ There are many approaches to the adjuvant hormonal therapy of breast cancer supported by large trials. No one approach is uniquely superior to others. Longer follow-up may lead to more specific recommendations. Adjuvant hormonal therapy for women with hormone receptor positive breast cancer plays a critical role in the management of early stage hormone receptor positive breast cancer.